Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:57 UTC |
---|
HMDB ID | HMDB0015336 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Flumazenil |
---|
Description | Flumazenil is only found in individuals that have used or taken this drug.Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in man. |
---|
Structure | CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1 InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3 |
---|
Synonyms | Value | Source |
---|
Anexate | ChEBI | Flumazenilo | ChEBI | Flumazenilum | ChEBI | Lanexat | ChEBI | Romazicon | Kegg | Anexic acid | Generator | Hoffman-la roche brand OF flumazenil | HMDB | Flumazepil | HMDB | Roche brand OF flumazenil | HMDB | Hoffman la roche brand OF flumazenil | HMDB |
|
---|
Chemical Formula | C15H14FN3O3 |
---|
Average Molecular Weight | 303.2884 |
---|
Monoisotopic Molecular Weight | 303.101919534 |
---|
IUPAC Name | ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate |
---|
Traditional Name | flumazenil |
---|
CAS Registry Number | 78755-81-4 |
---|
SMILES | CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1 |
---|
InChI Identifier | InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3 |
---|
InChI Key | OFBIFZUFASYYRE-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as imidazo[1,5-a][1,4]benzodiazepines. Imidazo[1,5-a][1,4]benzodiazepines are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzodiazepines |
---|
Sub Class | 1,4-benzodiazepines |
---|
Direct Parent | Imidazo[1,5-a][1,4]benzodiazepines |
---|
Alternative Parents | |
---|
Substituents | - Imidazo[1,5-a][1,4]benzodiazepine
- Para-diazepine
- Imidazole-4-carbonyl group
- Aryl fluoride
- Aryl halide
- Benzenoid
- N-substituted imidazole
- Azole
- Heteroaromatic compound
- Vinylogous amide
- Tertiary carboxylic acid amide
- Imidazole
- Carboxamide group
- Carboxylic acid ester
- Lactam
- Azacycle
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Organonitrogen compound
- Organooxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organofluoride
- Organic oxygen compound
- Organohalogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 201 - 203 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 1.04 g/L | Not Available | LogP | 1.9 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Flumazenil GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-3490000000-d0d0177798f08c7ec17a | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Flumazenil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Flumazenil GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Flumazenil LC-ESI-qTof , Positive-QTOF | splash10-0lg0-3890000000-2453b74fd469fb228589 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Flumazenil , positive-QTOF | splash10-0kdi-1293000000-7a192ee695af1d78e7bd | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Flumazenil , positive-QTOF | splash10-0kdi-0193000000-a02a88da5dbc9ae8b8a5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Flumazenil , positive-QTOF | splash10-0lg0-3890000000-2453b74fd469fb228589 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Flumazenil 35V, Positive-QTOF | splash10-0pxr-0290000000-d4bd11c45454f089d4e9 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 10V, Positive-QTOF | splash10-0udi-0039000000-512256f7d9c74da3dba9 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 20V, Positive-QTOF | splash10-0pb9-2094000000-2d484b39bd1b420cc821 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 40V, Positive-QTOF | splash10-0006-4950000000-0e25df1f3bb12b6672c9 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 10V, Negative-QTOF | splash10-0zfr-2098000000-b0cd088a553670984014 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 20V, Negative-QTOF | splash10-0pb9-2092000000-d4159177fc35a792370a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 40V, Negative-QTOF | splash10-0a71-3790000000-b679dafe637ef0296213 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 10V, Positive-QTOF | splash10-0udi-0029000000-ea5ff0185619f28dfa79 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 20V, Positive-QTOF | splash10-0pb9-0095000000-53b3b234fff80e66c40a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 40V, Positive-QTOF | splash10-055r-0390000000-e81718d47d5a3874b74b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 10V, Negative-QTOF | splash10-0udi-0019000000-a44687b430e97e86bb72 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 20V, Negative-QTOF | splash10-0pc0-0093000000-3aaa035c9d0947af6126 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Flumazenil 40V, Negative-QTOF | splash10-08fr-0290000000-06260a3ca1602bf6180f | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Ngo AS, Anthony CR, Samuel M, Wong E, Ponampalam R: Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department? Resuscitation. 2007 Jul;74(1):27-37. Epub 2007 Feb 15. [PubMed:17306436 ]
- Olkkola KT, Ahonen J: Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60. doi: 10.1007/978-3-540-74806-9_16. [PubMed:18175099 ]
- Maeda S, Miyawaki T, Higuchi H, Shimada M: Effect of flumazenil on disturbance of equilibrium function induced by midazolam. Anesth Prog. 2008 Fall;55(3):73-7. doi: 10.2344/0003-3006-55.3.73. [PubMed:18788841 ]
|
---|